EOSS Industries Holding GmbH
EOSS Management GmbH

A – 8010 Graz
Am Eisernen Tor 3
+43 316 269 205
office@eoss.at

7iD Technologies
www.7id.com

Bürocenter
www.eoss.at

EOSS Wireless
www.eoss.at

Innophore
www.innophore.com

Acceler8
www.acceler8.at

DevLabs
www.devlabs.ba

Fil Man Made Group
www.filmanmadegroup.com

Medovis Healthcare
www.medovis.at

ACL advanced commerce labs
www.acl.at

EOSS Immobilien
www.eoss.at

Genspeed Biotech
www.genspeed-biotech.com

nc digitalis
www.digitalis.at

PST Public Safety Technologies
www.pst.at

RANOREX
www.ranorex.com

Triestina Kurhotel
www.triestina.at

Wireless Montenegro http://www.wirelessmontenegro.com/

  

New Cooperation: GENSPEED Technology enables new rapid test for medical risk classification

Austrian GENSPEED Biotech GmbH and Virogates A/S (Nasdaq First North Denmark: VIRO) have commenced a partnership to develop a rapid test for the risk classification of acute and chronic patients on site.  The test targets to use GENSPEED technology to simultaneously analyze for C- Reactive Protein and suPAR from a finger prick in less than 10 minutes. Time-consuming laboratory tests are not needed. The test is suitable for on-site use in ambulances and general practitioners as well as in hospitals. 

A next-generation rapid test for reliable and precise laboratory-like  results on-site. 

GENSPEED Biotech offers a unique technology platform on which a new generation of rapid tests can be developed for medical diagnostics and various industrial applications. The technology combines microfluidics, miniaturized opto-electronics and automation as the proprietary basis of a small, simple, reliable and CE certified test system. The system enables the detection of up to 8 different analytes, such as bacteria, proteins or other biomarkers, in blood and other sample materials within a few minutes.

Dr. Max Sonnleitner, CEO of GENSPEED Biotech states: “With its ease of use and its multiplexing capabilities our certified Point-of-Care testing technology perfectly matches the requirements for outpatient triaging. We are convinced that this test will provide enormous added value to patients and health care systems worldwide!”

Link to GENSPEED Press Release